Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Reiterated (ARQT) at Strong Buy and Held Target at $16 on, Apr 12th, 2024
Serge Belanger of Needham, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $16 on, Apr 12th, 2024.
Serge has made no other calls on ARQT in the last 4 months.
There are 2 other peers that have a rating on ARQT. Out of the 2 peers that are also analyzing ARQT, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jonathan Block of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Wednesday, February 28th, 2024
This is the rating of the analyst that currently disagrees with Serge
- Uy Ear of "Mizuho" Reiterated at Strong Buy with Increased Target to $17 on, Wednesday, February 28th, 2024
